Daijiworld Media Network – Mumbai
Mumbai, May 5: Emerging research is indicating that psychedelic substances such as psilocybin and LSD may offer a new pathway for people struggling to quit smoking, one of the world’s most addictive habits.
Nicotine, the primary addictive component in tobacco, is considered as addictive as substances like cocaine and heroin. While nearly 70 per cent of smokers express a desire to quit, fewer than 10 per cent succeed each year, highlighting the need for more effective treatments.
Recent studies suggest that psychedelics could play a role in breaking this cycle. Researchers have found that such substances may trigger profound psychological shifts, helping individuals reassess their habits and priorities. Many participants reported that after psychedelic experiences, smoking no longer aligned with their values or sense of self.
“The magnitude of the experience can overshadow what previously felt like an insurmountable challenge,” said Matthew Johnson, professor of psychiatry and behavioural science at Johns Hopkins University.
In a March 2026 study, therapy combined with a single dose of psilocybin—the psychoactive compound in “magic mushrooms”—was found to be significantly more effective than therapy paired with nicotine patches. Participants who received psilocybin had six times higher odds of quitting smoking after six months compared to those using patches.
Earlier smaller trials have also shown promising results. In one study, up to 80 per cent of participants remained smoke-free six months after undergoing psilocybin-assisted therapy, far exceeding typical success rates of around 35 per cent with conventional methods.
Experts believe psychedelics may work by altering perception and behaviour patterns rather than directly addressing physical addiction. Participants often describe a sense of “reprogramming” or a shift in mindset that reduces the urge to smoke.
However, researchers caution that the science is still evolving. Psychedelics remain illegal in many countries, and their use in treatment is strictly regulated. Questions also remain about how these substances work, whether results can be replicated on a larger scale, and what long-term effects may be.
Despite these uncertainties, the findings have generated interest among scientists and clinicians. “There hasn’t been a new smoking cessation medication in decades, so the potential here is exciting,” said Megan Piper, a clinical psychology professor at the University of Wisconsin.
Psychedelics have also been studied for treating other forms of addiction, including alcohol and opioid dependence, with some early success.
With smoking continuing to be a leading preventable cause of death worldwide, researchers say innovative approaches like psychedelic-assisted therapy could become an important tool—pending further study and regulatory approval.